Wpływ suplementacji diety selenem na przebieg autoimmunologicznego zapalenia tarczycy – przegląd badań klinicznych przeprowadzonych w populacji europejskiej
References
- Caturegli P., De Remigis A., Chuang K., Dembele M., Iwama A., Iwama S.: Hashimoto’s thyroiditis: Celebrating the centennial through the lens of the Johns Hopkins Hospital surgical pathology records. Thyroid, 2013; 23: 142-150
- Hiromatsu Y., Satoh H., Amino N.: Hashimoto’s thyroiditis: History and future outlook. Hormones, 2013; 12: 12-18
- Pearce E.N., Farwell A.P., Braverman L.E.: Thyroiditis. N. Engl. J. Med., 2003; 348: 2646-2655
- Bülow Pedersen I., Knudsen N., Carlé A., Schomburg L., Köhrle J., Jørgensen T., Rasmussen L.B., Ovesen L., Laurberg P.: Serum selenium is low in newly diagnosed Graves’ disease: A population-based study. Clin. Endocrinol., 2013; 79: 584-590
- Glattre E., Nygård J.F., Aaseth J.: Selenium and cancer prevention: Observations and complexity. J. Trace Elem. Med. Biol., 2012; 26: 168-169
- Rasmussen L.B., Schomburg L., Köhrle J., Pedersen I.B., Hollenbach B., Hög A., Ovesen L., Perrild H., Laurberg P.: Selenium status, thyroid volume, and multiple nodule formation in an area with mild iodine deficiency. Eur. J. Endocrinol., 2011; 164: 585-590
- Wu Q., Rayman M.P., Lv H., Schomburg L., Cui B., Gao C., Chen P., Zhuang G., Zhang Z., Peng X., Li H., Zhao Y., He X., Zeng G., Qin F., Hou P., Shi B.: Low population selenium status is associated with increased prevalence of thyroid disease. J. Clin. Endocrinol. Metab., 2015; 100: 4037-4047
- Aaseth J., Frey H., Glattre E., Norheim G., Ringstad J., Thomassen Y.: Selenium concentrations in the human thyroid gland. Biol. Trace Elem. Res., 1990; 24: 147-152
- Bermano G., Nicol F., Dyer J.A., Sunde R.A., Beckett G.J., Arthur J.R., Hesketh J.E.: Tissue-specific regulation of selenoenzyme gene expression during selenium deficiency in rats. Biochem. J., 1995; 311: 425-430
- Schomburg L.: Selenium, selenoproteins and the thyroid gland: Interactions in health and disease. Nat. Rev. Endocrinol., 2011; 8: 160-171
- Gärtner R., Gasnier B.C., Dietrich J.W., Krebs B., Angstwurm M.W.: Selenium supplementation in patients with autoimmune thyroiditis decreases thyroid peroxidase antibodies concentrations. J. Clin. Endocrinol. Metab., 2002; 87: 1687-1691
- Gärtner R., Gasnier B.C.: Selenium in the treatment of autoimmune thyroiditis. Biofactors, 2003; 19: 165-170
- Duntas L.H., Mantzou E., Koutras D.A.: Effects of a six month treatment with selenomethionine in patients with autoimmune thyroiditis. Eur. J. Endocrinol., 2003; 148: 389-393
- Turker O., Kumanlioglu K., Karapolat I., Dogan I.: Selenium treatment in autoimmune thyroiditis: 9-month follow-up with variable doses. J. Endocrinol., 2006; 190: 151-156
- Mazokopakis E.E., Papadakis J.A., Papadomanolaki M.G., Batistakis A.G., Giannakopoulos T.G., Protopapadakis E.E., Ganotakis E.S.: Effects of 12 months treatment with L-selenomethionine on serum anti-TPO levels in patients with Hashimoto’s thyroiditis. Thyroid, 2007; 17: 609-612
- Karanikas G., Schuetz M., Kontur S., Duan H., Kommata S., Schoen R., Antoni A., Kletter K., Dudczak R., Willheim M.: No immunological benefit of selenium in consecutive patients with autoimmune thyroiditis. Thyroid, 2008; 18: 7-12
- Balázs C., Fehér J.: The effect of selenium therapy on autoimmune thyroiditis. Clin. Exp. Med. J., 2009; 3: 269-277
- Nacamulli D., Mian C., Petricca D., Lazzarotto F., Barollo S., Pozza D., Masiero S., Faggian D., Plebani M., Girelli M.E., Mantero F., Betterle C.: Influence of physiological dietary selenium supplementation on the natural course of autoimmune thyroiditis. Clin. Endocrinol., 2010; 73: 535-539
- Krysiak R., Okopien B.: The effect of levothyroxine and selenomethionine on lymphocyte and monocyte cytokine release in women with Hashimoto’s thyroiditis. J. Clin. Endocrinol. Metab., 2011; 96: 2206-2215
- Anastasilakis A.D., Toulis K.A., Nisianakis P., Goulis D.G., Kampas L., Valeri R.M., Oikonomou D., Tzellos T.G., Delaroudis S.: Selenomethionine treatment in patients with autoimmune thyroiditis: A prospective, quasi-randomised trial. Int. J. Clin. Pract., 2012; 66: 378-383
- Eskes S.A., Endert E., Fliers E., Birnie E., Hollenbach B., Schomburg L., Köhrle J., Wiersinga W.M.: Selenite supplementation in euthyroid subjects with thyroid peroxidase antibodies. Clin. Endocrinol., 2014; 80: 444-451
- Pilli T., Cantara S., Schomburg L., Cenci V., Cardinale S., Heid E.C., Kühn E.C., Cevenini G., Sestini F., Fioravanti C., D’Hauw G., Pacini F.: IFNγ-inducible chemokines decrease upon selenomethionine supplementation in women with euthyroid autoimmune thyroiditis: Comparison between two doses of selenomethionine (80 or 160 μg) versus placebo. Eur. Thyroid J., 2015; 4: 226-233
- Esposito D., Rotondi M., Accardo G., Vallone G., Conzo G., Docimo G., Selvaggi F., Cappelli C., Chiovato L., Giugliano D., Pasquali D.: Influence of short-term selenium supplementation on the natural course of Hashimoto’s thyroiditis: Clinical results of a blinded placebo-controlled randomized prospective trial. J. Endocrinol. Invest., 2017; 40: 83-89
- Pirola I., Rotondi M., Cristiano A., Maffezzoni F., Pasquali D., Marini F., Coperchini F., Paganelli M., Apostoli P., Chiovato L. i wsp.: Selenium supplementation in patients with subclinical hypothyroidism affected by autoimmune thyroiditis: Results of the SETI study. Endocrinol. Diabetes Nutr., 2020; 67: 28-35
- Manevska N., Stojanoski S., Makazlieva T.: Selenium treatment effect in auto-immune hashimoto thyroiditis in macedonian population. J. Endocrinol. Metab., 2019; 9: 22-28
- Krohn K., Maier J., Paschke R.: Mechanisms of disease: Hydrogen peroxide, DNA damage and mutagenesis in the development of thyroid tumors. Nat. Clin. Pract. Endocrinol. Metab., 2007; 3: 713-720
- Hendriksen M.A., van Raaij J.M., Geleijnse J.M., van den Hooven C.W., Ocké M.C., van der A D.: Monitoring salt and iodine intakes in Dutch adults between 2006 and 2010 using 24 h urinary sodium and iodine excretions. Public Health Nutr., 2014; 17: 1431-1438
- Karunasinghe N., Han D.Y., Zhu S., Yu J., Lange K., Duan H., Medhora R., Singh N., Kan J., Alzaher W., Chen B., Ko S., Triggs C.M., Ferguson L.R.: Serum selenium and single-nucleotide polymorphisms in genes for selenoproteins: Relationship to markers of oxidative stress in men from Auckland, New Zealand. Genes Nutr., 2012; 7: 179-190
- Jablonska E., Gromadzinska J., Reszka E., Wasowicz W., Sobala W., Szeszenia-Dabrowska N., Boffetta P.: Association between GPx1 Pro198Leu polymorphism, GPx1 activity and plasma selenium concentration in humans. Eur. J. Nutr., 2009; 48: 383-386
- de Farias C.R., Cardoso B.R., de Oliveira G.M., de Mello Guazzelli I.C., Catarino R.M., Chammas M.C., Cozzolino S.M., Knobel M.: A randomized-controlled, double-blind study of the impact of selenium supplementation on thyroid autoimmunity and inflammation with focus on the GPx1 genotypes. J. Endocrinol. Invest., 2015; 38: 1065-1074
- Curran J.E., Jowett J.B., Elliott K.S., Gao Y., Gluschenko K., Wang J., Abel Azim D.M., Cai G., Mahaney M.C., Comuzzie A.G. i wsp.: Genetic variation in selenoprotein S influences inflammatory response. Nat. Genet., 2005; 37: 1234-1241
- Bretz J.D., Arscott P.L., Myc A., Baker J.R.Jr.: Inflammatory cytokine regulation of Fas-mediated apoptosis in thyroid follicular cells. J. Biol. Chem., 1999; 274: 25433-25438
- Mezosi E., Wang S.H., Utsugi S., Bajnok L., Bretz J.D., Gauger P.G., Thompson N.W., Baker J.R.Jr.: Interleukin-1β and tumor necrosis factor (TNF)-α sensitize human thyroid epithelial cells to TNF-related apoptosis-inducing ligand-induced apoptosis through increases in procaspase-7 and bid, and the down-regulation of p44/42 mitogen-activated protein kinase activity. J. Clin. Endocrinol. Metab., 2004; 89: 250-257
- Wang S.H., Van Antwerp M., Kuick R., Gauger P.G., Doherty G.M., Fan Y.Y., Baker J.R.Jr.: Microarray analysis of cytokine activation of apoptosis pathways in the thyroid. Endocrinology, 2007; 148: 4844-4852
- Antonelli A., Ferrari S.M., Giuggioli D., Ferrannini E., Ferri C., Fallahi P.: Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun. Rev., 2014; 13: 272-280
- Santos L.R., Durães C., Mendes A., Prazeres H., Alvelos M.I., Moreira C.S., Canedo P., Esteves C., Neves C., Carvalho D., Sobrinho-Simões M., Soares P.: A polymorphism in the promoter region of the selenoprotein Sgene (SEPS1) contributes to Hashimoto’s thyroiditis susceptibility. J. Clin. Endocrinol. Metab., 2014; 99: E719-E723
- Wasniewska M., Vigone M.C., Cappa M., Aversa T., Rubino M., De Luca F., Study Group for Thyroid diseases of Italian Society for Pediatric Endocrinology: Acute suppurative thyroiditis in childhood: Relative frequency among thyroid inflammatory diseases. J. Endocrinol. Invest., 2007; 30: 346-347
- De Luca F., Santucci S., Corica D., Pitrolo E., Romeo M., Aversa T.: Hashimoto’s thyroiditis in childhood: Presentation modes and evolution over time. Ital. J. Pediatr., 2013; 39: 8
- Bonfig W., Gärtner R., Schmidt H.: Selenium supplementation does not decrease thyroid peroxidase antibody concentration in children and adolescents with autoimmune thyroiditis. Sci. World J., 2010; 10: 990-996
- Nourbakhsh M., Ahmadpour F., Chahardoli B., Malekpour-Dehkordi Z., Nourbakhsh M., Hosseini-Fard S.R., Doustimotlagh A., Golestani A., Razzaghy-Azar M.: Selenium and its relationship with selenoprotein P and glutathione peroxidase in children and adolescents with Hashimoto’s thyroiditis and hypothyroidism. J. Trace Elem. Med. Biol., 2016; 34: 10-14
- Stagnaro-Green A.: Approach to the patient with postpartum thyroiditis. J. Clin. Endocrinol. Metab., 2012; 97: 334-342
- Korevaar T.I., Schalekamp-Timmermans S., de Rijke Y.B., Visser W.E., Visser W., de Muinck Keizer-Schrama S.M., Hofman A., Ross H.A., Hooijkaas H., Tiemeier H., Bongers-Schokking J.J., Jaddoe V.W., Visser T.J., Steegers E.A., Medici M., Peeters R.P.: Hypothyroxinemia and TPO-antibody positivity are risk factors for premature delivery: The generation R study. J. Clin. Endocrinol. Metab., 2013; 98: 4382-4390
- Thangaratinam S., Tan A., Knox E., Kilby M.D., Franklyn J., Coomarasamy A.: Association between thyroid autoantibodies and miscarriage and preterm birth: Meta-analysis of evidence. BMJ, 2011; 342: d2616
- Negro R., Greco G., Mangieri T., Pezzarossa A., Dazzi D., Hassan H.: The influence of selenium supplementation on postpartum thyroid status in pregnant women with thyroid peroxidase autoantibodies. J. Clin. Endocrinol. Metab., 2007; 92: 1263-1268
- Mao J., Pop V.J., Bath S.C., Vader H.L., Redman C.W., Rayman M.P.: Effect of low‑dose selenium on thyroid autoimmunity and thyroid function in UK pregnant women with mild‑to‑moderate iodine deficiency. Eur. J. Nutr., 2016; 55: 55-61
- Karanikas G., Schuetz M., Wahl K., Paul M., Kontur S., Pietschmann P., Kletter K., Dudczak R., Willheim M.: Relation of anti-TPO autoantibody titre and T-lymphocyte cytokine production patterns in Hashimoto’s thyroiditis. Clin. Endocrinol., 2005; 63: 191-196
- Pállinger E., Csaba G.: A hormone map of human immune cells showing the presence of adrenocorticotropic hormone, triiodothyronine and endorphin in immunophenotyped white blood cells. Immunology, 2008; 123: 584-589
- Rotondi M., Chiovato L., Romagnani S., Serio M., Romagnani P.: Role of chemokines in endocrine autoimmune diseases. Endocr. Rev., 2007; 28: 492-520
- Antonelli A., Ferrari S.M., Frascerra S., Di Domenicantonio A., Nicolini A., Ferrari P., Ferrannini E., Fallahi P.: Increase of circulating CXCL9 and CXCL11 associated with euthyroid or subclinically hypothyroid autoimmune thyroiditis. J. Clin. Endocrinol. Metab., 2011; 96: 1859-1863
- Antonelli A., Ferrari S.M., Frascerra S., Galetta F., Franzoni F., Corrado A., Miccoli M., Benvenga S., Paolicchi A., Ferrannini E., Fallahi P.: Circulating chemokine (CXC motif) ligand (CXCL)9 is increased in aggressive chronic autoimmune thyroiditis, in association with CXCL10. Cytokine, 2011; 55: 288-293
- Antonelli A., Ferri C., Ferrari S.M., Frascerra S., Ruffilli I., Caponi L., Ulisse S., Miccoli M., Miccoli P., Fallahi P.: High levels of circulating chemokine (C-X-C motif) ligand 11 are associated with euthyroid or subclinically hypothyroid autoimmune thyroiditis and with chemokine (C-X-C motif) ligand 10. J. Interferon Cytokine Res., 2012; 32: 74-80
- Antonelli A., Rotondi M., Fallahi P., Romagnani P., Ferrari S.M., Buonamano A., Ferrannini E., Serio M.: High levels of circulating CXC chemokine ligand 10 are associated with chronic autoimmune thyroiditis and hypothyroidism. J. Clin. Endocrinol. Metab., 2004; 89: 5496-5499
- Nanba T., Watanabe M., Inoue N., Iwatani Y.: Increases of the Th1/Th2 cell ratio in severe Hashimoto’s disease and in the proportion of Th17 cells in intractable Graves’ disease. Thyroid, 2009; 19: 495-501
- Phenekos C., Vryonidou A., Gritzapis A.D., Baxevanis C.N., Goula M., Papamichail M.: Th1 and Th2 serum cytokine profiles characterize patients with Hashimoto’s thyroiditis (Th1) and Graves’ disease (Th2). Neuroimmunomodulation, 2004; 11: 209-213
- Konca Degertekin C., Aktas Yilmaz B., Balos Toruner F., Kalkanci A., Turhan Iyidir O., Fidan I., Yesilyurt E., Cakır N., Kustimur S., Arslan M.: Circulating Th17 cytokine levels are altered in Hashimoto’s thyroiditis. Cytokine, 2016; 80: 13-17
- Li D., Cai W., Gu R., Zhang Y., Zhang H., Tang K., Xu P., Katirai F., Shi W., Wang L., Huang T., Huang B.: Th17 cell plays a role in the pathogenesis of Hashimoto’s thyroiditis in patients. Clin. Immunol., 2013; 149: 411-420
- Xue H., Yu X., Ma L., Song S., Li Y., Zhang L., Yang T., Liu H.: The possible role of CD4+CD25highFoxp3+/CD4+IL-17A+ cell imbalance in the autoimmunity of patients with Hashimoto thyroiditis. Endocrine, 2015; 50: 665-673
- Wichman J., Winther K.H., Bonnema S.J., Hegedüs L.: Selenium supplementation significantly reduces thyroid autoantibody levels in patients with chronic autoimmune thyroiditis: A systematic review and meta-analysis. Thyroid, 2016; 26: 1681-1692
- Winther K.H., Wichman J.E.M., Bonnema S.J., Hegedüs L.: Insufficient documentation for clinical efficacy of selenium supplementation in chronic autoimmune thyroiditis, based on a systematic review and meta-analysis. Endocrine, 2017; 55: 376-385
DOI: https://doi.org/10.2478/ahem-2021-0027 | Journal eISSN: 1732-2693
Language: English
Page range: 683 - 695
Submitted on: Sep 22, 2020
Accepted on: Jul 8, 2021
Published on: Oct 30, 2021
Published by: Hirszfeld Institute of Immunology and Experimental Therapy
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
Related subjects:
© 2021 Jadwiga Kryczyk-Kozioł, Paweł Zagrodzki, Paweł Paśko, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.